S_M6R1 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152839

S_M6R1 Cell Line

Cat. #: 152839

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Bone

Disease: Cancer

Model: Cancer Model


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: John Lunec

Institute: Newcastle University

Tool Details

Tool Details


  • Name: S_M6R1 Cell Line
  • Cancer: Sarcoma
  • Cancers detailed: Multipotential sarcoma;Osteosarcoma
  • Research fields: Apoptosis and autophagy;Cancer;Cell biology;Drug development;Genetics
  • Tool sub type: Continuous
  • Parental cell: SJSA-1
  • Organism: Human
  • Tissue: Bone
  • Disease: Cancer
  • Model: Cancer Model
  • Conditional: No
  • Description: To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, MI-63, and a clonal resistant cell line was generated. The p53 mediated responses of the parental and resistant cell line were compared. In contrast to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was not observed in the SJSA-1 derived cell line, S-M6R1.
  • Production details: Resistant cell lines were established by exposing SJSA-1 cells to MI-63. Single cell derived colonies were isolated with cloning cylinders and the clonal population expanded in culture medium containing the MDM2/p53 antagonist refreshed weekly for 60 days. Stage 1 resistant clones were then further exposed to increased concentrations of MI-63 for 30 days to generate stage 2 resistant clones.
  • Biosafety level: 1
  • Cellosaurus id: CVCL_HG09


  • Format: Frozen
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes


  • TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
  • Drummond et al. 2016. Oncotarget. :. PMID: 27323823.